Compare EH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | RIGL |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | China | United States |
| Employees | 483 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.5M | 564.7M |
| IPO Year | 2019 | 2000 |
| Metric | EH | RIGL |
|---|---|---|
| Price | $9.37 | $28.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $22.47 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 522.9K | 397.1K |
| Earning Date | 05-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $33.23 | N/A |
| Revenue Next Year | $73.83 | $12.75 |
| P/E Ratio | ★ N/A | $64.55 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $9.04 | $18.14 |
| 52 Week High | $20.44 | $52.24 |
| Indicator | EH | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 46.60 |
| Support Level | $9.15 | $28.08 |
| Resistance Level | $10.68 | $31.89 |
| Average True Range (ATR) | 0.42 | 1.96 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 23.17 | 39.02 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.